Fiche du document
30 octobre 2020
- handle: 10670/1.l98ovy
- hal: hal-04482423
- doi: 10.1097/TP.0000000000003508
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1097/TP.0000000000003508
Mots-clés
-bio]Citer ce document
Jonathan Messika et al., « COVID-19 in Lung Transplant Recipients », HALSHS : archive ouverte en Sciences de l’Homme et de la Société, ID : 10.1097/TP.0000000000003508
Métriques
Partage / Export
Résumé
Background. A concern about the susceptibility of immunocompromised patients to the worldwide pandemic of coronavirus disease 2019 (COVID-19) has been raised. We aimed at describing COVID-19 infections in the French cohort of lung transplant (LT) patients. Methods. Multicenter nationwide cohort study of all LT recipients with COVID-19 diagnosed from March 1 to May 19, 2020. Recipient main characteristics and their management were retrieved. Hospitalization characteristics, occurrence of complications and survival were analyzed. Results. Thirty-five LT patients with a COVID-19 infection were included. Median age was 50.4 (40.6–62.9) years, 16 (45.7%) were female, and 80% were double-LT recipients. Infection was community-acquired in 25 (71.4%). Thirty-one (88.6%) required hospitalization, including 13 (41.9%) in the intensive care unit. The main symptoms of COVID-19 were fever, cough, and diarrhea, present in 71.4%, 54.3%, and 31.4% of cases, respectively. Extension of pneumonia on chest CT was moderate to severe in 51.4% of cases. Among the 13 critically ill patients, 7 (53.9%) received invasive mechanical ventilation. Thrombotic events occurred in 4 patients. Overall survival rate was 85.7% after a median follow-up of 50 days (41.0–56.5). Four of 5 nonsurvivors had had bronchial complications or intensification of immunosuppression in the previous weeks. On univariate analysis, overweight was significantly associated with risk of death (odds ratio, 16.0; 95% confidence interval, 1.5-170.6; P = 0.02). Conclusions. For the 35 LT recipients with COVID-19, the presentation was severe, requiring hospitalization in most cases, with a survival rate of 85.7%.